Research in Dr. James Freeman's lab focuses on basic and
translational studies related to pathobiology and therapy of pancreatic cancer.
Cancer cells undergo cellular plasticity in response to environmental stresses
and chemotherapy. Plasticity involves a phenotypic switch with cells undergoing
an epithelial to mesenchymal transition an expressing stem cell markers.
consequences of this switch are resistant to chemotherapy and more highly invasive
cancer cell. Thus one adverse effect of chemotherapy can by the development of
a subpopulation of cancer cells that are more aggressive. Our studies focus on
understanding the molecular events that regulate this switch and development of
strategies to block phenotypic switching as a means of improving therapy.
Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman
JW. Inhibiting signaltransducer and activator of transcription-3 increases response to gemcitabineand delays progression of pancreatic cancer. Mol Cancer. 2013 Sep
Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW,
Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined Targeting ofSTAT3/NF-ÎºB/COX-2/EP4 for Effective Management of Pancreatic Cancer.Cancer
Res. 2014 Mar 1;20(5):1259-73.
Zhao S, Cao L, Freeman JW. Knockdown of RON receptorkinase delays but does not prevent tumor progression while enhancing HGF/METsignaling in pancreatic cancer cell lines. Oncogenesis. 2013 Oct 7;2:e76.
Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW,
Nawrocki ST. Reolysinis a novel reovirus-based agent that induces endoplasmic reticularstress-mediated apoptosis in pancreatic cancer. Cell Death Dis. 2013 Jul
Bera A, Zhao S, Cao L, Chiao PJ, Freeman, JW.
OncogenicK-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-ÎºB Axis thatinduces expression of MMP9 and uPA in human pancreas progenitor cells. PLoS
One. 2013 Dec 5;8(12):e82282.